Blocking a specific receptor on immune cells to improve cancer treatment
Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity
This study is looking at how stopping a certain signal in immune cells can help your body fight tumors better, using a special method that injects treatments right into the tumors, which could lead to more effective cancer therapies for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10828406 on NIH RePORTER |
What this research studies
This research investigates how blocking the IL10 receptor on innate immune cells can enhance the body's immune response against tumors. By using a method called in situ vaccination, which involves injecting treatments directly into tumors, the study aims to improve the effectiveness of existing cancer therapies. The approach focuses on overcoming barriers posed by inhibitory signals that prevent immune cells from attacking cancer cells. Patients may benefit from a more effective treatment option that harnesses their own immune system to fight cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who have not responded well to current immune therapies.
Not a fit: Patients with cancers that are not amenable to immune-based therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment options that enhance the body's natural ability to fight tumors.
How similar studies have performed: Other research has shown promising results with similar immune modulation approaches, indicating potential for success in this area.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Khalil, Danny — Sloan-Kettering Inst Can Research
- Study coordinator: Khalil, Danny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.